Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 14, 2008

Lilly Pays $7M Upfront for Transition’s Diabetic Program

  • Transition Therapeutics could reap over $137 million through a collaboration with Eli Lilly covering diabetes compounds. Eli Lilly will initially pay $7 million for the exclusive, worldwide rights to Transition’s gastrin-based therapeutic portfolio.

    The agreement includes TT-223, which is in early clinical development. The candidate is being evaluated in combination with an EGF analogue and a GLP-1 analogue in type 1/2 diabetes as well as metformin in type 2 diabetes. Transition and Lilly will jointly conduct the planned Phase II study in type 2 diabetes. Thereafter, Lilly will be responsible for development and commercialization of all gastrin-based therapeutic products worldwide.

    Gastrin-based therapies provide sustained improvement in glycemic control in preclinical models and early clinical studies, according to the firms.



Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »